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Abstract
Breast cancer is the most aggressive form of all cancers, with high incidence and mortality rates. The purpose of the present
study was to investigate the molecular mechanism by which methylsulfonylmethane (MSM) inhibits breast cancer growth in
mice xenografts. MSM is an organic sulfur-containing natural compound without any toxicity. In this study, we
demonstrated that MSM substantially decreased the viability of human breast cancer cells in a dose-dependent manner.
MSM also suppressed the phosphorylation of STAT3, STAT5b, expression of IGF-1R, HIF-1a, VEGF, BrK, and p-IGF-1R and
inhibited triple-negative receptor expression in receptor-positive cell lines. Moreover, MSM decreased the DNA-binding
activities of STAT5b and STAT3, to the target gene promoters in MDA-MB 231 or co-transfected COS-7 cells. We confirmed
that MSM significantly decreased the relative luciferase activities indicating crosstalk between STAT5b/IGF-1R, STAT5b/
HSP90a, and STAT3/VEGF. To confirm these findings in vivo, xenografts were established in Balb/c athymic nude mice with
MDA-MB 231 cells and MSM was administered for 30 days. Concurring to our in vitro analysis, these xenografts showed
decreased expression of STAT3, STAT5b, IGF-1R and VEGF. Through in vitro and in vivo analysis, we confirmed that MSM can
effectively regulate multiple targets including STAT3/VEGF and STAT5b/IGF-1R. These are the major molecules involved in
tumor development, progression, and metastasis. Thus, we strongly recommend the use of MSM as a trial drug for treating
all types of breast cancers including triple-negative cancers.
Citation: Lim EJ, Hong DY, Park JH, Joung YH, Darvin P, et al. (2012) Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and
STAT5b Pathways. PLoS ONE 7(4): e33361. doi:10.1371/journal.pone.0033361
Editor: Jun Li, Sun Yat-sen University Medical School, China
Received October 20, 2011; Accepted February 7, 2012; Published April 2, 2012
Copyright:  2012 Lim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the Next generation BioGreen 21 Program (No. PJ0081062011), by the Rural Development Administration,
and partially supported by the Ministry of Commerce, Industry and Energy through the Bio-Food and Drug Research Center at Konkuk University, Glocal Campus,
South Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ymyang@kku.ac.kr
. These authors contributed equally to this work.
Introduction
Breast cancer (BC) is the major cancer affecting females in the
United States. Additionally, more than 1 million women
worldwide are diagnosed with this disease per year. BC is the
second most common cause of cancer-related deaths with
,400,000 patients dying due to this disease every year [1,2].
This disease is the major cause of death in women between the
ages 45 and 55 y [3]. Approximately, 15% of BCs are triple-
negative breast cancer, a type that is more prevalent among young
African, African-American, and Latino women [4]. This type of
aggressive breast cancer has unique molecular profiles. This
subtype is clinically negative about the expression of estrogen
receptor (ER) and progesterone receptor (PR), and does not over-
express human epidermal growth factor receptor-2 (Her-2)
protein. No targeted therapies exist for treating TNBC, and this
disease frequently displays distinct patterns of metastasis [3].
Human BC frequently expresses the epidermal growth factor
(EGF) receptor. Human epidermal growth factor-2 (Her-2), -3,
and -4, orphan receptors of the EGF receptor family, that are co-
expressed with other EGF receptors. The proto-oncogene Her-2 is
located on chromosome 17. In case of 25 – 30% breast cancers,
Her-2 is over-expressed. Apart from this, over-expression of Her-2
has been reported in many other aggressive breast cancers [5].
Ligand binding activates these receptors so that they form homo/
heterodimers and stimulate downstream signalling pathways. The
Ras/Raf/MAPK and PI3-K/Akt pathways involved in cell
proliferation, and survival are major targets of activated EGF
receptors [6]. Her-2 over-expression has been shown to result in
increased transformation, tumorigenicity, proliferation, and in-
vasiveness [7].
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+/
PR
+, whereas less than 5% are ER
2/PR
+ [8]. PR is a specific
receptor that belongs to the superfamily of ligand-activated
nuclear receptors [9]. PR exists in two isoforms, PR-A and PR-
B; both are expressed in humans [10]. Both receptors bind
progestins and promote epithelial cell proliferation as well as
lobulo-alveolar development [11]. The binding of progesterone to
PRs induces the formation of receptor homo- or heterodimers.
This conformational change leads to increased receptor phos-
phorylation, and interaction with target gene promoters, specific
co-activators, and general transcription factors [12]. PRs have
some prognostic and predictive implications [13,14]. Together
with ERs, PRs make cells sensitive or resistance to different
therapies [15]. Based on the expression pattern, PR breast cancer
may be ER
+/PR
+ or ER
+/PR
2, and PR
+ breast cancers have
been found to be more differentiated than PR
- breast cancers [8].
High levels of estrogen receptor-a (ER-a) promote hormone-
dependent tumor growth by converting the receptor as a ligand-
dependent transcription factor. ER-a-dependent processes require
different concentrations of receptors and is not always the factor
limiting hormone responsiveness. In breast tumors, increased
proliferation rates have been observed with high ER-a expression
[16] and thymidine kinase activity [17]. The ER-a receptor and
steroid hormones regulate vascular endothelial growth factor
(VEGF) in breast cancer in vivo [8].
Vascular endothelial growth factor-A (VEGF-A) is considered to
be the most important and potent pro-angiogenic factor involved
in tumor growth [19]. The binding of VEGF to VEGFR induces
conformational changes in the receptor followed by auto-
phosphorylation of the receptor [20]. VEGF expression is
regulated by hypoxia, steroid hormones, nitric oxide, and
cytokines [21,22].
Signal transducer and activator of transcription 3 (STAT3) is
important for breast involution after weaning [23] and a prognostic
factor for breast cancer [24]. We have reported that STAT3
modulates VEGF through HIF-1a [25]. Tumor angiogenesis is
enhanced as VEGF expression is up-regulated by increased
STAT3 activity. In addition, decreased Src-induced VEGF
expression is observed when Stat3 signaling is blocked [26]. This
indicates that Stat3 represents a common anti-angiogenesis target
for blocking multiple signaling pathways in human cancers.
Another important member of the STAT family, STAT5b,
regulates growth, differentiation, and survival of mammary and
solid tumors. Recently, we reported that STAT5b regulates the
transactivation of cyclin D1 and IGF-1 upon hypoxia stimulation
in breast cancer cells [27,28,29].
Methylsulfonylmethane (MSM) is a very simple organic sulfur-
containing compound with a molar mass of 94.13 g/mol. MSM
contains only eleven atoms and is found in foods, including fruits,
vegetables, grains, and beverages [30]. It is a symmetric molecule
with no isomeric forms. Dimethyl sulfone has also been detected in
the human brain [31], blood plasma, and cerebrospinal fluid [32]
by proton magnetic resonance spectroscopy. MSM is volatile,
easily lost during cooking, and is believed to be non-toxic [33,34].
MSM decreases arthritis pain and improves physical function of
osteoarthritis human knees without major adverse events [35].
This compound has also been found to be effective for treating
allergies [36], osteoarthritis pain [35], inflammation [37], re-
petitive stress injuries [38], and bladder disorders like intestinal
cystitis [39]. MSM can induce wound healing, contact inhibition,
and can block the ability of cells to migrate through the extra-
cellular matrix. Furthermore, it can restore anchorage-dependent
growth and irreversible senescence followed by arborization with
melanosomes in arbors seen in murine melanoma cell lines [40].
In this study, we proposed that MSM suppresses tumor growth
via inhibition of the STAT3 and STAT5b pathways. To test this
hypothesis, we investigated the effects of MSM on human breast
cancer cells and in the experimental animal model. The effects of
MSM on the expression of STAT3, STAT5b, and their
downstream targets were analysed. From the results obtained,
we found that MSM down-regulates triple-negative hormone
receptor expression in hormone-responsive cell lines and sup-
presses the growth of breast cancer xenografts through its multi-
targeted action.
Materials and Methods
Ethics Statement
All procedures for animal experiment were approved by the
Committee on the Use and Care on Animals (Certificate No:
KUB00313, Institutional Animal Care and Use Committee,
Seoul, Korea) and performed in accordance with the institution
guidelines.
Materials
Methylsulfonemethane (MSM) was purchased from Fluka/
Sigma Co. (St. Louis, MI).
Antibodies and Reagents
Dulbecco’s modified eagle’s medium (DMEM), DMEM/F-12,
RPMI 1640, 10% fetal bovine serum (FBS) and trypsin-EDTA
were purchased from Gibco-BRL (GrandIsland, NY). L-15
medium, anti-actin antibody, insulin and EGF were obtained
from Sigma Chemical (St. Louis, MO). Anti- STAT5b antibodies,
secondary antibodies (goat anti-mouse IgG-horseradish peroxi-
dase) were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Anti-phospho-STAT3(Tyr705) and Anti-phospho-IGF-
1R(Tyr1131) antibodies were obtained from cell signaling
(Beverly, MA). Anti-phospho-STAT5b(Tyr699) antibodies was
obtained from upstate (Lake Placid, NY). The secondary antibody
(horseradish peroxidase-conjugated donkey anti-rabbit IgG), the
enhanced chemiluminescence (ECL plus) detection kit was
purchased from Amersham Pharmacia Biotech. (Piscataway, NJ).
Restore
TM Western Blot Stripping Buffer and NE-PER kit were
purchased from Pierce (Rockford, IL). The luciferase assay
substrates, reporter lysis buffer, and electrophoretic mobility shift
assay (EMSA) kit were purchased from Promega Corp. (Madison,
WI). FuGene 6 transfection reagent was from Roche (Basel,
Switzerland), RNeasy mini kit and Qiaprep spin miniprep kits
were purchased from Qiagen (Germany).
Cell Culture
MCF-10A (kind gift from Dr. Ssang-Goo Cho, Konkuk
University, Korea), immortalized normal human breast epithelial
cells were grown to confluency in phenol red free DMEM/F2
medium supplemented with cholera toxin (20 mg/mL), insulin
(10 mg/mL), EGF (250 mg/mL), 1% penicillin/streptomycin, and
horse serum (5%). MCF-7 (No: 30022, KCLB, Korea), T-47D
(No: 30133, KCLB, Korea) and SK-BR3 (No: 30030, KCLB,
Korea), human breast cancer cells, were grown to confluency in
RPMI 1640 medium containing 10% FBS, insulin (5 N g/ml), and
EGF (10 ng/ml). COS-7 (No: 21651, KCLB, Korea), monkey
kidney cells, and MDA-MB 231 (No: 30026, KCLB, Korea),
human breast cancer cells, were cultured in DMEM containing
10% FBS, 2 mM glutamine, and 100 U/ml penicillin and
streptomycin at 37
˚
Ci n5 %C O 2. At the start of each experiment,
the cells were resuspended in the medium at a density of 2.5610
5
cells/ml.
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Cell viability was assayed by measuring blue formazan that was
metabolized from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide (MTT) by mitochondrial dehydrogenase, which is
active only in live cells. One day before drug application, cells
were seeded in 96-well flat-bottomed microtiter plates (3,000–
5,000 cells/well). Cells were incubated for 24 h with various
concentrations of MSM. MTT (5 mg/ml) was added to each well
and incubated for 4 h at 37uC. The formazan product was
dissolved by adding 200 ml dimethylsulfoxide (DMSO) to each
well, and the plates were read at 550 nm. All measurements were
performed in triplicate, and each experiment was repeated at least
three times.
Apoptosis Analysis
Fluorescein-conjugated Annexin V (Annexin V-FITC) was used
to quantitatively determine the percentage of cells undergoing
apoptosis. Treated cells were washed twice with cold PBS and then
resuspended in binding buffer at a concentration of 1x10
6 cells/
ml. Five microliters of Annexin V-FITC and 10 ml of propidium
iodide were added to suspended cells. After incubation for 15 min
at room temperature in the dark, the percentage of apoptotic cells
was analyzed by flow cytometry (Becton-Dickinson FACScan, San
Jose, CA). For positive controls 10 mM camptothecin and 23 mM
actinomycin D were used.
Total Cell Lysis
Breast cancer cells were treated with MSM for determined
times. Cells were lysed on ice for 10 min in radioimmunopreci-
pitation assay (RIPA) lysis buffer containing protease and
phosphatase inhibitors. Cells were disrupted by aspiration through
a 23-gauge needle, and centrifuged at 15,000 rpm for 10 min at
4uC to remove cellular debris. Protein concentations were
measured using the Bradford method.
Western Blot
Whole cell extracts (WCE) from breast cancer cells were
prepared by described previously and quantified using Bradford’s
method. Equal amounts of protein obtained by total lysis were
subjected to 10% SDS-PAGE and electrophoretically transferred
onto a nitrocellulose membrane. The blots were blocked with 5%
skim milk or BSA in TBS-T buffer. It was then incubated
overnight with primary antibody followed by washing with TBS-T
and incubation with secondary antibody (anti-mouse or anti rabbit
IgG HRP conjugate, 1:1,000 dilutions with skim milk or BSA).
Detection was done by using enhanced chemiluminescence (ECL
plus) detection kit.
Reverse Transcription Polymerase Chain Reaction (RT-
PCR)
Total RNA was isolated from the cells by using Tri reagent
(Sigma Chemical Co., St. Louis, MO) and quantitated spectro-
photometrically at 260 nm. RT-PCR analysis for VEGF, IGF-1R
and 18s RNA was performed (Table S1). Briefly, 1 mg of RNA was
reverse transcribed, and nested PCR was carried out by using 2 ml
of cDNA. The PCR condition consisted of denaturation for 1 min
at 94uC, annealing for 1 min at 58uC, and extension for 1 min at
72uC. RT-PCR products were analyzed on 1% agarose gel stained
with ethidium bromide.
Electrophoretic Mobility Shift Assay (EMSA)
STAT5 and STAT3 DNA binding activity was detected using
an electrophoretic mobility shift assay (EMSA), in which a labeled
double-stranded DNA sequence was used as a DNA probe to bind
active STAT5b and STAT3 protein in nuclear extracts. Nuclear
protein extracts were prepared with the Nuclear Extract Kit
(Panomics, AY2002). EMSA experiment is performed by in-
cubating a biotin-labeled transcription factor (TF-STAT5 and
STAT3) probe with treated and untreated nuclear extracts.
Co-transfection and Luciferase Assay
The expression vectors for mouse STAT5b (pMX/STAT5b;
kindly provided by Dr. Koichi Ikuta, Kyoto University, Japan)
were constructed as previously described. cDNA for STAT5b was
inserted into the EcoR?and Sal?sites of the pMX vector. IGF-1R
(kindly provided by Dr. Haim Werner, Tel Aviv University, Israel)
genomic DNA fragments, including nucleotides -2350 to +640
(nucleotide 1 corresponds to the transcription start site of the rat
IGF-1R gene), was sub-cloned upstream of a promoterless firefly
luciferase reporter in the pGL2P vector (Promega, Madison, WI).
For reporter gene assays, COS-7 cells were transiently co-
transfected with the plasmid pGL2P, IGF-1R or HSP90a (kindly
provided by Dr. Carrie Shemanko, Calgary University, Canada)
construct and the STAT5b expression vector.
Cells were co-transfected with various combinations the
following constructs; wild-STAT3 (gifts from Dr. Shong, Chung-
nam National University, Korea); the VEGF reporter construct
containing 2.7 kb of the VEGF promoter region. Transfected cells
were washed with ice-cold PBS, lysed, and lysates were used
directly to measure luciferase activity. The luciferase activity of
each sample was determined by measuring luminescence for 10 s
on a Lumat LB 9507 luminometer (EG&G Berthold, Oak Ridge,
TN). The experiments were performed in triplicate, and similar
results were obtained from at least three independent experiments.
Live Cell Microscopy
Cells were plate on 6 well culture dishes and incubated at 37uC,
5% CO2. Time series (10 min) of phase contrast images were
acquired at a video rate of 1 frame/5s with a Real-time cell
observer (Carl Zeiss). Time series of cells with and without
methylsulfonylmethane were obtained at 0-120 min after adding
the compound and every 24 h for up to four days.
Tumorigenicity
All procedures for animal experiment were approved by the
Committee on the Use and Care on Animals (Institutional Animal
Care and Use Committee, Seoul, Korea) and performed in
accordance with the institution guidelines. MDA-MB 231 tumor
xenograft were established by subcutaneously inoculating 1x10
7
cells into the right flanks of 5-week-old Balb/c nude mice (Orient
Bio, Seongnam-Si, Korea). When tumors reached between 6 to
8 mm in diameter, mice were randomly assigned to control group,
MSM 3%-treated group and MSM 5%- treated group respectively
with 6 mice in each group. The drug was administered as
intragastric injections of 100 ml, containing 3% MSM or 5%
MSM in triple distilled water. The injections were repeated one
time every other day. Tumor growth was monitored by periodic
measurements with calipers. Tumor volume was calculated using
the formula: tumor volume (mm
3)=maximal length (mm) 6
(perpendicular width) (mm
2)/2. Animals were sacrificed when the
diameter of tumors reached 2 cm or after 30 days of treatment. In
our experiments, no mice were observed to be died of tumor
loading. All available human breast cancer xenograft collected
from mice were reviewed and included in the study.
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Total RNA was isolated from tumor xenograft and quantified
by a spectrophotometric analysis at 260 nm. The cDNA synthesis
and the probe used for the detection of IGF-1 and b-actin from
a TaqMan gene expression assay kit (Applied Biosystems Inc.).
PCR was monitored in real time using the ABI Prism 7900 HT
Real time PCR System (Applied Biosystems Inc., CA).
Immunohistochemistry
Formalin-fixed paraffin-embedded breast tumor xenografts
were sliced into 5 mm thick section. These sections were
deparaffinized with 100% xylene, rehydrated with decreasing
concentration of ethyl alcohol, permeabilised with 0.1% triton X-
100 and blocked with 10% NGS (Nomal Goat Serum in PBS).
These were then incubated with the STAT5b, IGF-1R, STAT3
and VEGF antibody followed by incubation with the secondary
antibody, Alexa Fluor 488 (rabbit) and Alexa Fluor 594 (mouse)
(Invitrogen). For the detection of nuclear level, tissue sections were
incubated on DAPI for one minute and rinsed with PBS. Samples
were observed and photographed under the fluorescent micro-
scope.
Data analysis and Statistics
The results of the experiments are expressed as mean 6 SEM.
Statistical analysis was done by t-tests or ANOVA-tests using the
SAS program.
Results
Cytotoxicity of MSM in Human Breast Cancer Cell Line
To determine the effect of MSM on cell survival, human breast
cancer cell lines MDA-MB 231 and SK-BR3 were exposed to
different concentrations of MSM (100, 300, and 500 mM) for
24 h. The number of MSM treated cells during the logarithmic
phase of growth was compared with that of the control cells.
MDA-MB 231 cell growth was inhibited by ,55% with 300 mM
MSM and ,70% with 500 mM MSM (Fig. 1A). SK-BR3 cell
growth was inhibited by ,38% with 300 mM MSM and ,70%
with 500 mM MSM (Fig. 1B). Thus, treatment with MSM
substantially decreased the viability of MDA–MB 231 and SK-
BR3 cells in a dose-dependent manner.
MSM-induced Apoptosis in MDA-MB 231 Cells
MTT assay on MDA-MB 231 and SK-BR3 showed that MSM
had high levels of cytotoxic activity. To differentiate this from
necrosis and to confirm it as apoptosis, we performed fluorescein-
conjugated annexin V (annexin V-FITC) flow cytometry. We
quantitated the number of cells undergoing apoptosis. Our results
showed that 300 mM of MSM induced apoptosis in 50% of the
MDA-MB 231 cells (Fig. 1C). The positive control camptothecin
(10 mM) and actinomycin D (23 mM) induced apoptosis approx-
imately 65% and 81% respectively.
Expression of Stats and Triple-negative Receptors are
down-regulated by MSM
The expression of STAT proteins and triple-negative hormone
receptors was down-regulated in response to MSM in a dose-
dependent manner in non-aggressive tumor cells like SK-BR3,
MCF-7, and T-47D (Fig. 2A). In MDA-MB 231 cells expression of
STAT proteins decreased. The expression of IGF-1R decreased in
the entire breast cancer cell lines treated with 300 mM of MSM
whereas it found unaltered in normal cell line MCF-10A. This was
also observed for STAT5b and STAT3. The STAT5 phosphor-
ylation level also found unaltered by MSM in MCF-10A cells. The
expression of triple-negative hormone receptors, Her-2, ER-a, and
PR as well found to be suppressed by 300 mM of MSM (Fig. 2B).
Igf-1R and Vegf mrna Expression are Down-regulated by
MSM
Rt-pcr for both MSM-treated and untreated cells yielded
amplified products of 312 and 522 bp, which corresponds to
VEGF and IGF-1R mRNA, respectively. igf-1r and vegf were
amplified using gene-specific primers. The expression of both igf-
1r and vegf was down-regulated in a dose-dependent manner by
MSM (Fig. 3). 18S expression (control) was unaffected by MSM
regardless of the concentration.
MSM Inhibited the Binding of STAT5 to the IGF-1R and
STAT3 to the VEGF Promoter sites
MSM inhibited the binding of STAT5 to the IGF-1R site and
suppressed STAT3 binding to the VEGF promoter sites. MDA-
MB 231 cells were treated with 300 mM MSM. As shown in
Fig. 4A, no DNA binding activity was found in the presence of 300
mM MSM. The nuclear extract showed decreased level of p-
STAT5 (Fig. 4C). Hence, MSM inhibited the phosphorylation of
STAT5b to p-STAT5, and binding to the promoter sites of IGF-
1R. Moreover, decreased binding of STAT3 to VEGF promoter
sites was detected (Fig. 4B), with very low expression levels of
STAT3 (Fig. 4C). Figure 4C apparently shows the expression of
prominent metastatic receptor VEGF-R2 blocked near complete-
ly, whereas the expression of tumor suppressor protein p53, and
BRCA-1were maintained.
MSM Inhibited STAT5b/IGF-1R, STAT5b/HSP90a, and
STAT3/VEGF Promoter Activities
The involvement of MSM in STAT3 mediated activation of the
VEGF promoter was examined using the STAT3-deficient cell
line, COS-7. The transcriptional effects of MSM on STAT5b/
IGF-1R, STAT5b/HSP90a, and STAT3/VEGF were deter-
mined with a luciferase reporter assay. Fig. 5A, B and C show the
relative luciferase activities of STAT5b/IGF-1R, STAT5b/
HSP90a, and STAT3/VEGF, respectively. After 24 h of MSM
(300 mM) treatment, relative luciferase activity was decreased and
found to be statistically significant for STAT5b/IGF-1R,
STAT5b/HSP90a and STAT3/VEGF (***P ,0.001). These
results suggest that STAT5b is a critical mediator of the IGF-1R,
and STAT3 is of the VEGF pathway. It also confirms the critical
role of MSM in inhibiting the promoter activities of STAT5b and
STAT3, there by inhibiting the STAT5b and STAT3 signalling
cascades.
MSM Induced Migration Inhibition in Metastatic Human
Breast Carcinoma Cells
According to the cytotoxic studies, we confirmed the IC50
dosage of MSM as 300 mM (Fig. 1A). For getting the maximum
number of viable cells, we reduced the concentration of MSM to
200 mM. In this concentration, MSM induced cytotoxicity up to
30% of MDA-MB 231 cells and 70% of MDA-MB 231 cells
remained viable (Data not shown). This gave us an opportunity to
decipher the actions of MSM. Live cell video microscopy
demonstrated that metastatic breast cancer cells in 200 mM
MSM stopped migrating through the adjacent layers of metastatic
cells. The live cell microscopy also showed high morphological
alterations in the control cells on continuous incubation for 72 h
with a media change in every 24 h. After 72 h incubation, the
morphology of control cells changed to sharp finger-like structures
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the migration. However, the 200 mM MSM treated cells remained
without any morphological alterations (Fig. 6Bii). Moreover, the
result clearly shows the cells grown under the absence of MSM
(control) migrate under and over neighboring cells (Fig. 6Bi; Movie
S1) whereas the MSM treated cells lost its ability for migration
(Fig. 6Bii; Movie S2). Apart from this, the result gave an additional
evidence of the ability of MSM to control the cell proliferation and
apoptosis (Fig. 6).
MSM Suppressed the Growth of Human Breast Cancer
Xenografts
The in vivo tumor suppressive activity of MSM was evaluated in
Balb/c mice bearing breast tumors induced by MDA-MB 231 cells
(1x10
7 cells/mL). Three separate groups of animals were studied,
and MSM treatment started 2 weeks after the injection of human
breast cancer cell line (MDA-MB 231). After 30 days of treatment,
the diameter of tumor mass was measured. We observed a dose-
dependent suppression of tumor growth (Fig. 7A). A graph was
created showing the increase in tumor size with respect to the time
of MSM treatment in days. The rate of tumor growth in the
control group was significantly greater than that of the other two
groups (Fig. 7B). The animals were sacrificed, and the xenografts
were collected for further analysis.
IGF-1 Expression Changes in Xenografts by MSM
The xenografts were subjected to Real Time-PCR analysis
specific for IGF-1. The results showed that MSM inhibited the
expression of IGF-1 in the in vivo system (Fig. 7C). A statistically
significant reduction of IGF-1 expression was found in tissues from
mice treated with 300 mM MSM (***P ,0.001). Protein
expression studies of the tissue produced results similar to the
ones obtained from the in vitro analysis. The expression STAT5b,
STAT3, VEGF, and IGF-1 decreased while IGF-1R levels were
maintained (Fig. 7D). Down-regulation of VEGF expression by
MSM was confirmed in the tumor xenografts by RT-PCR analysis
(Fig. 7E). Immunohistochemistry specific for VEGF/STAT3 and
IGF-1R/STAT5b confirmed the ability of MSM to down-regulate
the expression of these factors (Fig. 8A and B). All of these results
complimented the one we obtained from the in vitro analysis.
Discussion
Cancer cells become resistant to different therapies over time;
thus, it is necessary to target multiple signaling points for effective
therapy. We have determined that MSM can inhibit STAT3/
VEGF and STAT5b/IGF-1R pathways, thereby suppressing the
growth of solid tumors. STAT3 is involved in tumor progression
by inducing angiogenic factors such as VEGF [26]. VEGF,
particularly VEGF-A, is considered to be the most important and
potent pro-angiogenic factor involved in tumor growth [19]. Anti-
angiogenic therapy appears to be a too narrow approach for
treating patients with cancer. Cancer cells may find compensatory
Figure 1. MSM induced cytotoxicity in human breast cancer cell lines in a dose-dependent manner. The cytotoxicity is confirmed as
apoptosis through flow cytometry. A, effect of MSM on triple-negative MDA-MB 231 cells. B, effect of MSM on SK-BR3 cells. C, flow cytometry of MDA-
MB 231 cells using Annexin V-FITC, propidium iodide flow cytometry.
doi:10.1371/journal.pone.0033361.g001
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should produce better results under such conditions. MSM was
found to have high levels of cytotoxic activity (Fig. 8) and anti-
angiogenic activity by suppressing VEGF. This compound can
halt tumor progression by blocking STAT5b and IGF-1R.
To evaluate the anti-cancer effects of MSM, we performed
MTT assay using different concentrations of MSM. The results
shown in Fig. 1A and 1B indicated that MSM exerted good
cytotoxic effects on metastatic human breast cancer cells (MDA-
MB 231) and comparatively less aggressive human breast cancer
cells (SK-BR3). The IC50 was found to be 300 mM. MSM is an
edible natural organic compound present in many food items and
is not associated with any toxic effect even at higher concentration
[33,34]. Because of this, we used high concentration of the drug
(300 mM) for further studies. Cytotoxicity resulting from MSM
was confirmed as apoptosis by annexin V-FITC flow cytometry
(Fig. 1C). These results were similar to the ones from a study by
Caron et al. on a metastatic murine melanoma cell line. In their
Figure 2. A, change in expression of STATs, IGF-1R, VEGF, BRCA, Brk, and hormone receptors in human breast cancer cells by MSM.
MSM substantially decreased the protein expression of human breast cancer cells in a dose-dependent manner. Whereas in normal cell line MCF-10A
(Panel 1), MSM did not alter the protein expression levels. B, expression of Her-2, ER-a and PR by MSM in human breast cancer cells SKBR-3, MCF-7,
and T-47D. The values are means 6 S.E (n=3) after normalization to b-actin levels (internal control). Asterisks indicate a statistically significant
decrease by t-test (**p,0.01). Cell lysates were separated by 10% SDS–PAGE and transferred to a nitrocellulose membrane. The membrane was
blotted with the primary antibody, then stripped and reprobed with the next antibody and so on. Data are one representative of three independent
experiments.
doi:10.1371/journal.pone.0033361.g002
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metastatic and anti-cancer activity. This finding was the first
report on metastatic anti-cancer effect of MSM [40]. In addition to
this, MSM may have dual function with anti-oncogenic effects and
active-tumor suppressing effects in the nuclear level of cancer cells
(Fig. 4C).
Anti-angiogenic studies of MSM in human breast cancer cells
were mainly focused on VEGF and its regulator STAT3. Western
blotting studies, DNA binding studies, luciferase assays, and
transcriptional level regulation studies were performed to analyze
the regulatory effects of MSM on STAT3 and VEGF. All results
showed that MSM can effectively control the expression and
activation of STAT3 and VEGF. The STAT nuclear translocation
Figure 3. RT-PCR analysis of breast cancer cell lines revealed MSM can effectively down regulate the expression of IGF-1R and VEGF
in dose dependent manner. A, IGF-1R and VEGF level in MDA-MB 231 cells. B, IGF-1R and VEGF level in SK-BR3 cells (table 1).
doi:10.1371/journal.pone.0033361.g003
Figure 4. DNA binding activities of STAT5 to IGF-1R and STAT3 to VEGF sites in transfected MDA-MB 231 cells were detected by
EMSA. A, binding activity of STAT5b to the STAT5 binding site (GAS-1) of IGF-1 promoter. B, binding activity of STAT3 on the VEGF promoter site. C,
nuclear protein extracts separated and blotted onto nitrocellulose membrane showing decrease in the level of p-STAT3 and p-STAT5.
doi:10.1371/journal.pone.0033361.g004
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serine phosphorylation, but they are affected by STAT tyrosine
phosphorylation [41]. Our study showed that MSM has the
capacity to regulate the phosphorylation of STAT3 and STAT5b
(Fig. 4C) and there by the remaining signaling cascades it mediates
too.
STAT5 up-regulates genes encoding apoptosis inhibitors and
cell cycle regulators, including Bcl-xL, cyclin D1, and p21 thus
leading to oncogenesis [42,43]. STAT5 has a major role in the
development, prognosis, prediction, and progression of breast
cancer [44]. In normal individuals, STAT5 is necessary for the
terminal differentiation of mammary glands and lactogenesis [45].
Novel functions of STAT5b, a new target for breast tumor kinase/
protein tyrosine kinase 6 (Brk/PTK6), have been reported [46]
and the involvement of STAT5b in breast cancer cell migration
has been demonstrated [47]. We previously reported that
STAT5b may mediate the transcriptional activation of IGF-1
and cyclin D1 after hypoxic stimulation in human breast cancer
cells [27,29,48]. Cyclin D1 has been shown to be regulated by
STAT5b [49]. Cyclin D1 and IGF -1R are the key regulators of
cell proliferation that are overexpressed in most breast cancers
[50]. Furthermore, IGF-1 is a potent mitogen in cancer cells and
plays an important role in tumorigenesis and tumor progression in
a variety of cancers [51,52].
The regulatory effects of MSM on tumorigenesis and tumor
progression were studied by examining STAT5b/IGF-1R.
Western blotting studies showed that MSM can effectively
down-regulate the expression of STAT5b as well as IGF-1R in
both aggressive and non-aggressive human breast cancer cell lines.
IGF-1R blockage using different approaches leads to dramatic
Figure 5. Activation of the STAT3/VEGF promoter related pathway in COS-7 cells by MSM. A, change of STAT5b/IGF-1R promoter. B,
change of STAT5b/HSP90a promoter and C, change of STAT3/VEGF promoter. Data represents means of at least three separate experiments. Asterisks
indicate a statistically significant decrease by ANOVA-test (***p,0.001).
doi:10.1371/journal.pone.0033361.g005
Figure 6. Methylsulfonylmethane induced migration inhibition
in metastatic breast cancer cell line MDA-MB 231. MDA-MB 231
cells (10
5 cells/ml) were plated into DMEM medium. After 24 h,
medium was replaced with DMEM with and without MSM. Ai, MDA-MB
231 cells without MSM. Live cell image acquired after 24 h Aii, MDA-MB
231 cells in 200 mM MSM. Live cell image acquired after 24 h. Bi, MDA-
MB 231 cells without MSM. Live cell image acquired after 72 h showing
the morphological changes like arborization. Bii, MDA-MB 231 cells in
200 mM MSM. Live cell image acquired after 72 h showing no
morphological alteration.
doi:10.1371/journal.pone.0033361.g006
Suppression of Breast Cancer Growth by MSM
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e33361reductions in proliferation and other neoplasia parameters [53,54].
Brk/PTK6 and HIF 1-a were also down-regulated by MSM
(Fig. 2), showing the multiple target action of this compound for
tumor suppression. RT-PCR and DNA binding studies showed
that IGF-1R expression was down-regulated. MSM suppressed the
activation of STAT5 and subsequent decreased DNA binding
activity was observed in STAT5/IGF-1R (Fig. 4). Luciferase assay
confirmed this finding by showing reduced activity of STAT5b/
IGF-1R (Fig. 5).
The morphological alterations happening to MDA-MB 231
cells were observed in the presence and absence of MSM with the
aid of live cell microscopy. According to the cytotoxic studies, we
confirmed the IC50 dosage of MSM as 300 mM (Fig. 1A). To
decipher further actions of MSM, we needed more live cells. So we
reduced the concentration of MSM to 200 mM. In this
concentration ,70% of MDA-MB 231 cells remained viable,
and this concentration used for live cell microscopic analysis. The
analysis performed for 72 h with media change in every 24 h. The
results obtained from live cell microscopy were surprising. MSM
inhibited the migration of metastatic breast cancer cell lines
(Movie S2). The cells which were not treated with MSM showed
migration over and under the neighboring layers (Movie S1).
Moreover, the control cells showed arborized morphology
(Fig. 6Bi), whereas the 200 mM MSM treated cells were remained
without any morphological alteration (Fig. 6Bii). These sharp
protrusions were believed as actin filaments, which were needed
for the migration of metastatic cells. The same result was observed
in Caron’s paper on metastatic murine melanoma cell line. In their
report, the authors state that 200 mM MSM induced contact
inhibition and migration inhibition in metastatic melanoma cell
line [40].
Triple-negative hormone receptors are very important in
human breast cancer because they can make tumors sensitive or
resistant to chemotherapy [15]. The mortality rate of patients with
triple-negative breast cancer is very high [55]. These hormonal
receptors are usually overexpressed in human breast cancers [56].
Therapy is usually designed based on the receptors responsible for
the malignancy. The remarkable ability of MSM is that this
compound can manage all types of malignancies associated with
hormone receptors. Western blotting studies on hormone re-
Figure 7. Breast cancer xenografts were established in mice by subcutaneous injection of MDA-MB 231 cells (1X10
7 cells per
mouse). A, image of tumor-xenografted nude mice model at the end of the treatment. B, tumor size growth curves during the treatment calculating
the volume size of individual tumors. C, real time PCR results of IGF-1 mRNA from breast cancer xenografts. The real time PCR was performed using
TaqMan Gene Expression assays for human IGF-1 and b-actin mRNAs from ABI on ABI 7900 HT Real-time PCR system. The values are means6S.E
(n=3) after normalization to b-actin mRNA levels (internal control). Asterisks indicate a statistically significant decrease by ANOVA-test (***p,0.001).
D, regulation of protein expression in xenografts by MSM. E, RT-PCR analysis of IGF-1R and VEGF mRNA levels in xenografts showed the
transcriptional regulation by MSM.
doi:10.1371/journal.pone.0033361.g007
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down-regulate the expression of triple-negative hormone receptors
(Fig. 2). In case of triple-negative cancer cells (MDA-MB 231),
tumor progression is controlled by modulating IGF-1R. MSM can
be used to treat herceptin-resistant breast cancers because the
resistance is induced by IGF-1R [57] and MSM effectively
controlled the expression of IGF-IR. So we hypothesized that
MSM can also be used as a trial drug for tumors over expressing
Her-2.
We performed in vivo studies to confirm the tumor suppressor
activity of MSM and to propose its use as a trail drug for
metastatic breast cancer therapy, especially for triple-negative
breast cancer. MDA-MB 231 cells were injected subcutaneously
into Balb/c nude mice for the induction of xenografts. After
30 days of treatment with MSM, these xenografts were removed
and subjected to tissue analysis. The morphological data showed
that MSM suppressed xenograft growth. In the presence of 300
mM MSM, xenograft growth was reduced by 70% compared to
the control animals (Fig. 7B). Multiple targets for MSM were
analyzed in vivo using Western blotting and RT-PCR. We found
the results from these studies to concur with the in vitro analysis
results (Fig. 7D and E). We also performed immunohistochemical
analysis of the xenograft in order to observe the expression
patterns of VEGF, STAT3, IGF-1R, and STAT5b (Fig. 8A and
B). These results also showed MSM can control VEGF, STAT3,
IGF-1R, and STAT5b effectively.
The live cell microscopic study confirmed the ability of MSM to
inhibit cell migration and in vivo studies with breast cancer
xenograft model confirmed the ability of MSM to suppress tumor
growth. Both from in vitro and in vivo analysis we confirmed that
MSM had a regulatory mechanism on STAT3, STAT5b, IGF-
1R, IGF-1, and VEGF. This confirmed the ability of MSM to
suppress tumor initiation, growth, and metastasis. Based on all
these results from our study, we strongly recommend the use of
MSM as a trial drug for treating breast cancers because of its
multi-targeting mechanism.
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